{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-252714","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.949353+00:00","generated_at":"2026-06-23T06:57:50.643367+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aura Biosciences doses first patient in Phase 1 study of AU-011 for bladder cancer","bullets":["First patient dosed in Phase 1 study of belzupacap sarotalocan (AU-011) for non-muscle invasive bladder cancer (NMIBC).","Phase 1 open-label trial to enroll approximately 23 adults; primary endpoint safety/tolerability.","Initial Phase 1 data expected in 2023; CMO notes no major advances in NMIBC in over two decades.","FDA granted Fast Track designation for AU-011 in NMIBC in June 2022.","Approximately 70% of bladder cancer patients are diagnosed early with NMIBC (global)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-252714","json":"https://secwatch.observer/filing/0001193125-22-252714.json","markdown":"https://secwatch.observer/filing/0001193125-22-252714.md","text":"https://secwatch.observer/filing/0001193125-22-252714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522252714/0001193125-22-252714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522252714/d363970d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:57:50.643367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}